Nasus Pharma advances epinephrine nasal spray toward pivotal trial

March 25, 2026 9:00 AM

Nasus Pharma Ltd. (NYSE: NSRX) reported positive Phase 2 results for its intranasal epinephrine powder NS002 and plans to initiate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found